Related Experiment Video

Updated: Oct 4, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

Exclusive modifications of NuMA in malignant epithelial cells: A potential therapeutic mechanism

Malka Cohen-Armon1

  • 1The Sackler School of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel-Aviv 69978, Israel.

Drug Discovery Today
|February 10, 2022
PubMed

Insights

The drug PJ34 targets nuclear mitotic apparatus (NuMA) protein, selectively killing cancer cells by disrupting mitotic spindle poles. This action is independent of PARP1 inhibition, challenging existing cancer treatment notions.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Cancer Therapeutics

Background:

  • Nuclear mitotic apparatus (NuMA) protein is crucial for mitosis in proliferating human cells.
  • Stable mitotic spindles depend on the bipolar clustering of NuMA.
  • The phenanthridine PJ34 targets NuMA and selectively kills malignant epithelial cells.

Purpose of the Study:

  • To investigate the mechanism by which PJ34 selectively induces cell death in malignant cells.
  • To explore the role of NuMA post-translational modification in PJ34's cytotoxicity.
  • To examine the relationship between PJ34's PARP1 inhibition activity and its cancer-killing effects.

Main Methods:

  • Treatment of malignant and benign human cells with PJ34.
  • Analysis of NuMA post-translational modification and protein-binding capacity.
  • Assessment of mitotic spindle pole integrity and cell death.
  • Evaluation of Poly (ADP-ribose) polymerase 1 (PARP1) inhibition activity.

Main Results:

  • PJ34 exclusively blocks NuMA post-translational modification in malignant epithelial cells, not benign cells.
  • This blockage impairs NuMA's binding capacity, leading to mitotic spindle defects.
  • PJ34 induces Mitotic Catastrophe and cell death in cancer cells.
  • PJ34 exhibits potent PARP1 inhibition but its cytotoxicity is PARP-independent.

Conclusions:

  • PJ34 selectively targets NuMA in cancer cells, causing Mitotic Catastrophe via spindle pole disruption.
  • The observed PARP-independent cytotoxicity of PJ34 challenges the established role of PARP1 inhibition in cancer therapy.
  • PJ34 highlights that some PARP1 inhibitors may exert anti-cancer effects through alternative mechanisms beyond DNA repair inhibition.
Keywords:
Human malignant epithelial cellsMitotic catastrophe cell deathMitotic spindleNuMAPARP1 inhibitorsPJ34

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K